UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 154

Sortiert nach

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2015-07, Vol.373 (3), p.209-219

2015

Volltextzugriff (PDF)

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Volltextzugriff (PDF)

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

The New England journal of medicine, 2018-11, Vol.379 (20), p.1926-1936

2018

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Annals of oncology, 2014-08, Vol.25 (8), p.1544-1550

2014

Volltextzugriff (PDF)

Managing the onset of a new disease in older age: Housing wealth, mortgage borrowing, and medication adherence

Social science & medicine (1982), 2022-12, Vol.314, p.115437-115437, Article 115437

2022

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Clinical cancer research, 2017-09, Vol.23 (18), p.5384-5393

2017

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

The New England journal of medicine, 2012-01, Vol.366 (4), p.299-309

2012

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (7), p.597-609

2020

Volltextzugriff (PDF)

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2961-2968

2016

Volltextzugriff (PDF)

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Annals of oncology, 2017-03, Vol.28 (3), p.497-504

2017

Volltextzugriff (PDF)

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1796-1804

2012

Volltextzugriff (PDF)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Annals of oncology, 2016-06, Vol.27 (6), p.1047-1054

2016

Volltextzugriff (PDF)

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

The lancet oncology, 2012-04, Vol.13 (4), p.e148-e160

2012

Volltextzugriff (PDF)

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Journal of clinical oncology, 2010-01, Vol.28 (1), p.105-113

2010

Volltextzugriff (PDF)

Increased incidence of vertebral fractures in German adults from 2009 to 2019 and the analysis of secondary diagnoses, treatment, costs, and in-hospital mortality

Scientific reports, 2023-04, Vol.13 (1), p.6984-6984, Article 6984

2023

Volltextzugriff (PDF)

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3351-3357

2011

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(144)

Publikationsform

Artikel
(154)

Sprache

Englisch
(152)
Japanisch
(27)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(154)
Female
(147)
Science & Technology
(147)
Middle Aged
(146)
Life Sciences & Biomedicine
(145)
Adult
(131)
Oncology
(103)
Breast Neoplasms - Drug Therapy
(83)
Breast Cancer
(67)
Breast Neoplasms - Pathology
(63)
Treatment Outcome
(57)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(55)
Tumors
(45)
Aged, 80 And Over
(43)
Neoadjuvant Therapy
(42)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(40)
Chemotherapy
(37)
Biological And Medical Sciences
(36)
Medical Sciences
(35)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Managing the onset of a new disease in older age: Housing wealth, mortgage borrowing, and medication adherence

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Increased incidence of vertebral fractures in German adults from 2009 to 2019 and the analysis of secondary diagnoses, treatment, costs, and in-hospital mortality

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Aktive Filter

Suchergebnisse filtern